Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | CN¥16,585,346 | CN¥13,690,811 | CN¥14,238,443 | CN¥16,425,571 |
| - Cash | CN¥6,821,398 | CN¥6,863,773 | CN¥7,120,399 | CN¥6,999,423 |
| + Debt | CN¥8,932,797 | CN¥8,238,503 | CN¥8,396,207 | CN¥7,303,856 |
| Enterprise Value | CN¥18,696,746 | CN¥15,065,542 | CN¥15,514,251 | CN¥16,730,004 |
| Revenue | CN¥2,005,468 | CN¥2,195,337 | CN¥1,725,715 | CN¥1,733,784 |
| % Growth | -8.6% | 27.2% | -0.5% | – |
| Gross Profit | CN¥295,470 | CN¥179,802 | CN¥184,705 | -CN¥191,845 |
| % Margin | 14.7% | 8.2% | 10.7% | -11.1% |
| EBITDA | CN¥148,061 | CN¥275,459 | CN¥288,838 | -CN¥106,982 |
| % Margin | 7.4% | 12.5% | 16.7% | -6.2% |
| Net Income | CN¥41,337 | CN¥39,254 | CN¥12,517 | -CN¥189,854 |
| % Margin | 2.1% | 1.8% | 0.7% | -11% |
| EPS Diluted | 0.004 | 0.004 | 0.001 | -0.02 |
| % Growth | 5.3% | 216.7% | 106% | – |
| Operating Cash Flow | CN¥165,401 | CN¥200,061 | -CN¥53,471 | CN¥0 |
| Capital Expenditures | -CN¥200,759 | -CN¥138,857 | -CN¥330,976 | -CN¥571,221 |
| Free Cash Flow | -CN¥35,359 | CN¥61,204 | -CN¥385,568 | CN¥33,933 |